BIONOMICS LIMITED - AM

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

08 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

Bionomics to Present at the 2024 CNS Summit

07 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

04 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

Bionomics to Present at the ThinkEquity Conference

23 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

14 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

07 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Bionomics Limited announces intention to re-domicile to the United States

01 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

31 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

29 Jul 2024 16:30:00 By Nasdaq GlobeNewswire

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

18 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Bionomics Limited Announces Private Placement of up to $70.0 Million

31 May 2024 08:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

20 May 2024 06:30:00 By Nasdaq GlobeNewswire

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

21 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at the 2024 BIO CEO & Investor Conference

22 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Bionomics Provides a Review of 2023 and of 2024 Plans

22 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at Biotech Showcase™ 2024

05 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

06 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

16 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

28 Sep 2023 06:00:52 By Nasdaq GlobeNewswire